Asides

GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that all senior executives and employees participated in Isofol’s share warrant program “2018” (series 2018/2022 and series 2018/2023). A total of 1,260,139 warrants with the right to subscribe for new shares in Isofol were acquired. Management and employees …

Isofol Reports All Employees Participate in Newly Created Share Warrant Program Read More »

GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from an open-label extension study for the ISO-CC-005 Phase 1/2a study of arfolitixorin in patients with metastatic colorectal cancer (mCRC). New results from 19 patients treated in the first-line setting showed early tumor shrinkage, defined as …

Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin Read More »

GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient has been enrolled in the pivotal Phase 3 AGENT clinical study evaluating arfolitixorin for the treatment of metastatic colorectal cancer (mCRC). AGENT is a randomized, controlled, multi-centre study with blinded independent review of the …

First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer Read More »

GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of Roger Tell, MD., PhD as Chief Scientific Officer (CSO) and Senior Vice President (SVP) of clinical development. Dr. Tell has more than a decade of experience as a clinical oncologist in addition to holding management …

Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development Read More »

GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the pivotal Phase 3 clinical trial, the ISO-CC-007 study, for the treatment of first-line (initial) metastatic colorectal cancer (mCRC). Anders Rabbe, chief executive officer of Isofol, said, “We look forward to bringing arfolitixorin to all patients …

Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer Read More »

Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an Extraordinary General Meeting on Wednesday 10 October. The present Chairman, Jan-Eric Österlund, is resigning and the Nomination Committee is proposing Dr Ulf Jungnelius as new Chairman. The Committee is also proposing an increased board with three new directors.   Isofol’s …

New Chairman and extended board at Isofol Medical AB (publ) Read More »